Infectious Disease Therapeutics Market Size & Share 2026 - 2034

Infectious Disease Therapeutics Market Size

The global infectious disease therapeutics market size was estimated at USD 139.6 billion in 2025. The market is expected to grow from USD 143.3 billion in 2026 to USD 190.1 billion in 2034, at a CAGR of 3.6%.

The infectious disease therapeutics market is experiencing sustained growth, driven by the increasing global burden of infectious diseases, the rising incidence of bacterial and viral infections, and the growing need for advanced infectious disease treatments. According to public health estimates, infectious diseases account for more than 13 million deaths annually worldwide, highlighting the critical demand for effective therapeutics across hospitals, clinics, and community healthcare settings. The infectious disease drug market is further supported by the rising prevalence of zoonotic diseases, with nearly 75% of emerging infectious diseases originating from animal-to-human transmission, creating significant opportunities within the zoonotic disease treatment market and veterinary infectious disease therapeutic market.

Additionally, the expanding elderly population, which is more vulnerable to infections due to age-related immune decline, continues to increase demand for antibiotics, antivirals, antifungals, antiparasitic drugs, and preventive therapies. Bacterial infections remain the largest contributor to the bacterial infection disease market, accounting for the majority of infectious disease cases globally and driving substantial demand for hospital infection therapeutics and targeted antimicrobial treatments.

Furthermore, the growing burden of HIV and other retroviral infections continues to strengthen the infectious disease treatment market, with millions of people requiring long-term therapeutic management. Advances in infectious disease diagnosis and treatment, including precision medicine, rapid diagnostics, and combination therapies, are improving clinical outcomes and accelerating market expansion across developed and emerging economies. As healthcare systems prioritize early detection, pathogen-specific therapies, and antimicrobial stewardship programs, the infectious disease therapeutics market is expected to witness robust growth, particularly across APAC infectious disease diagnosis & treatment markets where rising healthcare investments and disease surveillance initiatives are enhancing access to innovative treatment solutions.

Market Dynamics

Drivers

Rising incidences of infectious diseases
The increasing prevalence of bacterial, viral, fungal, and zoonotic infections is driving demand for effective infectious disease therapeutics and treatment solutions across hospitals and healthcare settings.

Increasing development of innovative therapeutics
Advancements in antivirals, biologics, immunotherapies, and targeted treatments are improving clinical outcomes and expanding the scope of the infectious disease drug market.

Opportunity

Rising investment in pandemic preparedness and expansion of antiviral and biologics pipelines
Governments and healthcare organizations are increasing investments in pandemic readiness, while expanding antiviral and biologics pipelines create opportunities for innovative treatment development.

Growth in rapid-response platforms and combination therapies
The adoption of rapid-response drug development platforms and combination treatment approaches is expected to improve therapeutic effectiveness and accelerate market expansion.

Restraint/Challenge

High treatment costs due to antimicrobial resistance
The growing burden of drug-resistant infections often requires complex and prolonged therapies, significantly increasing treatment costs for healthcare providers and patients.

Stringent regulatory approvals
Lengthy clinical trials and strict regulatory requirements can delay the approval and commercialization of new infectious disease therapeutics, impacting market growth.

Infectious Disease Therapeutics Market Trends

The infectious disease therapeutics market is expanding rapidly, driven by the rising global burden of bacterial, viral, fungal, and parasitic infections, along with increasing demand for advanced infectious disease diagnosis and treatment solutions. Growing awareness of public health preparedness, emerging infectious outbreaks, and hospital-acquired infections is accelerating investments across the infectious disease drug market and infectious disease treatment market. Technological advancements in molecular diagnostics, genomic sequencing, and point-of-care testing are enabling faster and more accurate detection of pathogens, supporting earlier intervention and improved patient outcomes. These innovations are particularly important in addressing complex conditions, zoonotic diseases, and antibiotic-resistant infections.

The increasing prevalence of antimicrobial resistance has intensified the need for next-generation anti-infective therapies, targeted drug delivery systems, and precision medicine approaches. In parallel, breakthroughs in vaccine development, immunotherapies, gene-based treatments, and microbiome research are transforming the infectious disease therapeutics market by providing more effective and personalized treatment options. Artificial intelligence (AI) and machine learning (ML) are further enhancing infectious disease management through predictive analytics, clinical decision support, and accelerated drug discovery, helping healthcare providers identify disease progression risks and optimize treatment strategies. Growing demand across hospital infection therapeutic applications, veterinary infectious disease therapeutic markets, and APAC infectious disease diagnosis and treatment sectors is creating new growth opportunities for industry participants.

Additionally, increasing emphasis on sustainable pharmaceutical manufacturing, biodegradable formulations, and environmentally responsible treatment development is reshaping innovation priorities. Collectively, these advances are strengthening the effectiveness, accessibility, and long-term growth potential of the global infectious disease therapeutics industry. 

Infectious Disease Therapeutics Market Analysis

Based on infection type, the global market is bifurcated into bacterial infection, viral infection, fungal infection and parasitic infection. The bacterial infection segment dominated the market in 2025 with USD 60.3 billion.
 

• The increasing prevalence of immune disorders and underlying health conditions largely attributed to unhealthy lifestyle habits is contributing to a surge in bacterial infections. Globally, bacterial infections are responsible for approximately 7.7 million deaths each year, underscoring the immediate need for effective treatment solutions. This growing health burden is significantly driving demand for infectious disease therapeutics.
   
• The rising cases of inadequate hygiene and food contamination results in bacterial infections that require infectious disease therapeutics, thereby further escalates the market growth. According to WHO, 600 million falls ill due to contaminated food every year leading to almost 1 in 10 deaths per year.
   
• Similarly, the growing challenge of antimicrobial resistance (AMR) has made infection treatment more complex, leading to prolonged cases of severe infectious disease. The World Bank estimates that by 2050, AMR could result in 10 million deaths per year globally, surpassing cancer as a leading cause of death. This further advances the demand for the bacterial disease therapeutics.

Learn more about the key segments shaping this market

Download Free PDF

Based on drug type, the global infectious disease therapeutics market is categorized into antibiotics, antivirals, antifungals, antiparasitic, vaccines and immunotherapies. The antibiotics segment dominated the market in 2025 and was valued at USD 49.4 billion.
 

• The increasing prevalence of bacterial infections has stimulated the demand for antibiotics as they are the primary treatment for these infections that vary from common infections such as pneumonia and urinary tract infections to more severe conditions such as sepsis and tuberculosis.
   
• For instance, the 2022 Global Antimicrobial Resistance and Use Surveillance System (GLASS) reported concerning resistance rates in common bacterial pathogens such as E. coli resistant to third-generation cephalosporins and methicillin-resistant Staphylococcus aureus.
   
• The rising incidences of antibiotic-resistant bacteria has expanded the demand for innovative antibiotics. As bacteria become resistant to older antibiotics, the need for new classes of antibiotics intensifies the growth in this segment.
   

Based on mode of administration, the global infectious disease therapeutics market is categorized into oral, parenteral and intranasal. The oral segment is growing with a significant CAGR and is expected to reach USD 115.7 billion by 2034.
 

• Oral medications are easy to administer compared to parenteral and intranasal dosage form, causing higher patient compliance. Adherence to oral therapies is significantly higher than for injectable treatments as patients prefer taking a pill at home rather than visiting healthcare facilities for injections.
   
• Oral medications are more cost-effective than parenteral treatments, as they require less infrastructure for administration and fewer healthcare resources. Oral health therapeutics can help reduce healthcare costs by minimizing the need for hospital visits and specialized medical staff required for administering injections, making them a more cost-effective option.
   

Based on distribution channel, the global infectious disease therapeutics market is bifurcated into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market with USD 63.4 billion in 2025 and is expected to reach USD 84.3 billion by 2034.
 

• Hospital pharmacies play a vital role in the treatment of various infectious diseases that require specialized medications such as intravenous antibiotics or antivirals for conditions such as sepsis, chickenpox, sexually transmitted infections and others.
   
• The hospital has severe cases of infection and are necessary for medical expertise for monitoring the diseases.
   
• Moreover, the increasing cases of hospital-acquired infections also contribute to the market for hospital pharmacies. Majority of the drugs used for treatment of infectious diseases especially the resistant infections are only available in hospital pharmacies.
   
• The medicines used for severe infections may not be accessible in retail or online pharmacies due to high potency drugs medications that require medical supervision during administration. This stimulates the market growth for hospital pharmacies in infectious disease therapeutic market.

In 2025, the U.S held a significant position in the North America infectious disease therapeutics market, valued at USD 53.2 billion.
 

• The rising incidence of infectious diseases is driven by an aging population and increasing antimicrobial resistance that has significantly contributed to the growing demand for infectious disease therapies.
   
• According to the Centers for Disease Control and Prevention (CDC), there are approximately 10.2 million physician visits annually for infectious and parasitic diseases, along with an estimated 3.8 million emergency department visits related to these conditions. These figures highlight the substantial healthcare burden and the need for effective therapeutic interventions.
   
• Also, the key players in the market are involved in research and development activities to develop next-generation antimicrobials, biologics and infectious disease-focused immunotherapies, that further contribute to the market growth.
   
• Moreover, advancements in vaccine technology by companies such as Pfizer are leading the mRNA-based vaccines that significantly impacted the market. The U.S. government provide initiatives such as the Biomedical Advanced Research and Development Authority (BARDA) continuously supports research and development in market.
   

Germany dominates the European infectious disease therapeutics market, showcasing strong growth potential.
 

• The increasing incidence of infectious disease in Germany, combined with strong government initiatives towards infection control programs and well-developed healthcare infrastructure, is stimulating growth in the market.
   
• For example, the German Infectious Disease Society (GSS) are actively working to increase awareness and enhancing treatment practices, thereby rising market uptake.
   
• Institutes such as Deutsches Zentrum für Infektionsforschung (DZIF) and the Robert Koch Institute (RKI) are focusing on emerging infections and developing new therapies. 
   
• Germany's robust pharmaceutical and biotechnology industry is majorly investing in research and development activities to introduce new infectious disease therapies such as precision targeted antimicrobials and immune modulating therapy. For instance, Curevac has a pipeline mainly focused on mRNA technology for treating infectious diseases.
   
• Moreover, the implementation of personalized infectious disease treatment strategies, such as genetic profiling and bio markers-based therapy selection, is greatly improving patient outcomes.
   

China infectious disease therapeutics market is estimated to grow with a significant CAGR, making it to be the fastest growing country in the Asia Pacific market.
 

• The increasing awareness of infectious disease management, government efforts toward early detection of infectious disease and increasing healthcare facilities have favoured the market expansion.
   
• The increasing collaborations with international biotech companies are facilitating the introduction of cutting-edge IV antibiotics, cytokines therapy and host-directed infectious disease treatment, thereby contributing the market growth.
   
• For instance, in May 2024, Zai Lab and Innoviva Specialty Therapeutics got National Medical Products Administration (NMPA) approval of Xacduro, the ongoing advancements in infectious disease therapeutics, specifically targeting drug-resistant pathogens. This approval brings focus on the increasing need for novel antibiotics in infectious disease treatment.
   
• China's increasing use of AI-based diagnostic tools and machine learning algorithms to predict infectious disease and improve treatment is also stimulating market growth.
   

Brazil leads the Latin American infectious disease therapeutics market, with remarkable growth during the analysis period.
 

• Brazil's high rate of infectious disease burden such as retrovirus and tuberculosis along with growing antimicrobial resistance rates have resulted in the incidence of infectious disease. The government of Brazil has implemented strict hospital infection control measures and species management guidelines for enhancing early diagnosis and treatment access.
   
• In addition, partnership with international pharma companies have increased access to new infectious disease therapies such as next-generation antibiotics and immunomodulators.
   
• The increased need for cost saving, infectious disease management solutions and increased public-private healthcare collaborations further escalate the market growth. For example, CDC Brazil is working closely with the MOH, Oswaldo Cruz Foundation (Fiocruz) and other partners for the detection, prevention and control infectious disease outbreaks to build and strengthen the country’s public health potentials.
   

Infectious Disease Therapeutics Market Share

Top 6 players such as Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, Abbott Laboratories and Sanofi accounts for approximately 60-70% of the market share. These players focus on various strategies such as business expansion, research and development activities, collaboration and novel product launches to consolidate their market presence.
 

For instance, in March 2025 the U.S. FDA approved GSK's antibiotic Blujepa for treating urinary tract infections caused by bacteria in women and girls aged 12 and older. This new drug targets UTI-causing bacteria such as E. coli and shows a lower risk of bacterial resistance. This helped the company expand its product offerings. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio.
 

Infectious Disease Therapeutics Market Companies

The company profile section includes companies that have commercial drug available in the market. Prominent players operating in the infectious disease therapeutics treatment market are as mentioned below:

• Abbott Laboratories
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck
• Novartis
• Pfizer
• Sandoz International
• Sanofi
   

To stay competitive, key players are investing in research and development for the development of advanced or novel infectious disease treatment solutions. These advancements are fostering increased competition, create awareness and simulating growth across the market. The key players in the industry are rising awareness, collaborating for infectious disease. For instance, in March 2022, Pfizer acquired Arena Pharmaceuticals for a USD 6.7 billion deal, focusing its immunology and therapeutic pipeline for infectious diseases.
 

Moreover, in December 2024, Gilead Sciences invested USD 20.1 million in Assembly Biosciences. The investment aimed to support Assembly's antiviral therapeutic projects, including treatments for herpesviruses and hepatitis B and D. This strategy is expected to enhance the company’s outreach to untapped economies.

Infectious Disease Therapeutics Industry News

• In February 2025 – CARB-X announced its 2025 funding round focused on combating infectious diseases and antimicrobial resistance, seeking innovative therapeutics for infections caused by Gram-negative pathogens and diagnostics for typhoid fever. The initiative aims to accelerate the development of next-generation anti-infective solutions targeting high-priority global health threats.
• In December 2025 – Mirum Pharmaceuticals announced an agreement to acquire Bluejay Therapeutics in a deal worth up to US$820 million, including US$250 million in cash, US$370 million in stock, and up to US$200 million in milestone payments. The acquisition strengthens Mirum’s infectious disease portfolio through brelovitug, a late-stage therapy for chronic hepatitis D. 

The infectious disease therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Infection Type

• Bacterial infection    
• Viral infection
  • Retroviral infection (HIV/AIDS)
  • Influenza
  • Hepatitis
  • Other viral infections 
• Fungal infection       
• Parasitic infection    

Market, By Drug Type

• Antibiotics
• Antivirals
• Antifungals
• Antiparasitic
• Vaccines
• Immunotherapies

Market, By Mode of Administration

• Oral
• Parenteral
• Intranasal

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE